Thiopyrane-4-ones as DNA protein kinase inhibitors

Details Thiopyrane-4-ones as DNA protein kinase inhibitors Thiopyrane-4-ones as DNA protein kinase inhibitors

2006-09-12

2006-09-12

Dentz, Bernard (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S432000, C544S145000, C549S028000, C604S020000

Reexamination Certificate

active

07105518

ABSTRACT:
The present invention provides compounds of formula (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof, wherein R1and R2are independently hydrogen, an option ally substituted C1-7alkyl group, C3-20heterocyclyl group, or C5-20aryl group, or may together form, along with the nitrogen atom to which they are attached, an optionally substituted heterocyclic ring having from 4 to 8 ring atoms; and R3is an optionally substituted C3-20heterocyclyl or C5-20aryl group, and their use as pharmaceuticals, particularly in treating diseases which are retroviral mediated or ameliorated by the inhibition of DNA-PK,

REFERENCES:
patent: 4954518 (1990-09-01), Takano et al.
patent: 5252735 (1993-10-01), Morris
patent: 5284856 (1994-02-01), Naik et al.
patent: 5302613 (1994-04-01), Morris
patent: 5703075 (1997-12-01), Gammill et al.
patent: 5733920 (1998-03-01), Mansuri et al.
patent: 5922755 (1999-07-01), Tanaka et al.
patent: 6348311 (2002-02-01), Kastan et al.
patent: 6387640 (2002-05-01), Kastan et al.
patent: 2004/0002492 (2004-01-01), Smith et al.
patent: 2004/0023968 (2004-02-01), Martin et al.
patent: 2004/0192687 (2004-09-01), Martin et al.
patent: 0 610 519 (1994-08-01), None
patent: 0 635 268 (1995-01-01), None
patent: 0 640 339 (1995-03-01), None
patent: 0 641 566 (1995-03-01), None
patent: 0 648 492 (1995-04-01), None
patent: 0 658 343 (1995-06-01), None
patent: 1303724 (1973-01-01), None
patent: 2 302 021 (1997-01-01), None
patent: 03215-423 (1990-01-01), None
patent: WO 90/06921 (1990-06-01), None
patent: WO 91/19707 (1991-12-01), None
patent: WO 92/00290 (1992-01-01), None
patent: WO 95/29673 (1995-11-01), None
patent: WO 96/01108 (1996-01-01), None
patent: WO 97/15658 (1997-05-01), None
patent: WO 97/018323 (1997-05-01), None
patent: WO 98/055602 (1998-12-01), None
patent: WO 98/056391 (1998-12-01), None
patent: WO 99/047494 (1999-09-01), None
patent: WO 01/53266 (2001-07-01), None
patent: WO 02/020500 (2002-03-01), None
patent: WO 02/20500 (2002-03-01), None
patent: WO 02/056912 (2002-07-01), None
patent: WO 03/024949 (2003-03-01), None
patent: WO03/093261 (2003-04-01), None
patent: WO 03/034997 (2003-05-01), None
patent: WO 03/035618 (2003-05-01), None
patent: WO 03/070726 (2003-08-01), None
Abraham, Robert T., “Cell cycle checkpoint signaling through the ATM and ATR kinases,”Genes&Dev., 15:2177-2196 (2001).
Archer, S. et al., “Ring-Hydroxylated Analogues of Lucanthone as Antitumore Agents,”J. Med Chem., 25, 220-227 (1982).
Brown, P.O., “Integration of retroviral DNA,”Curr Top Microbiol Immunol., 157:19-48 (1990).
Chiosis, G, et al. “LY294002-geldanamycin heterodiamers as selective inhibitors of the P13K and P13k-related family”,Bioorganic&Medicinal Chemistry Letters, vol. 11, No. 7, Apr. 9 2001 pp. 909-913, XP004232522.
Daniel, Rene, et al., “Wortmannin potentiates integrase-mediated killing of lymphocytes and reduces the efficiency of stable transduction by retroviruses,”Mol. Cell Biol, 21:4, 1164-1172 (2001).
Durocher, Daniel, and Jackson, Stephen P., “DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?,”Curr Opin Cell Biol., 13:225-231 (2001).
Giroux, A., et al, “One pot biaryl synthesisvia in situboronate formation,”Tet. Lett., 38:22, 3841-3844 (1997).
Griffin, et al., “Selective Benzopyranone and Pyrimido [2,1-a]isoquinolin-4-one Inhibitors of DNA-Dependent Protein Kinase: Synthesis, Structure—Activity Studies, and Radiosensitization of a Human Tumor Cell Line in Vitro”,J. Med. Chem., 2005, 48, 569-585.
Haselhorst, Dorte, et al., “Development of cell lines stably expressing human immunodeficiency virus type 1 proteins for studies in encapsidation and gene transfer,”J Gen Virol, 79:231-237 (1998).
Herzog, Karl-Heinz et al., “Requirement for ATM in ionizing radiation-induced cell death in the developing central nervous system,”Science, 280: 1089-1091 (1998).
Hickson, Ian, et al, “Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM,”Cancer Research64, Dec. 15, 2004, 9152-9159.
Ishiyama, T. et al., “Synthesis of arylboronates via the palladium(0)-catalyzed cross-coupling reaction of tetra(alkoxo)diborons with aryl triflates,”Tell. Lett., 38:19, 3447-3450 (1997).
Keith, Curtis T. and Schreiber, Stuart L., “PIK-related kinases: DNA repair, recombination, cell cycle checkpoints,”Science, 270:50-51 (1995).
Leahy, et al., “Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone librariest,”Bioorganic&Medicinal Chemistry Letters14 (2004) 6083-6087.
Metcalfe, Judith A. et al., “Accelerated telomere shortening in ataxia telangiectasia,”Nature Genetics, 13: 350-353 (1996).
Mlotkowska, B.L. et al., “Two-dimensional NMR studies of 2-substituted thioxanthene sulfoxides,”J. Heterocyclic Chem., 28: 731-736 (Apr.-May 1991).
Naldini, Luigi et al., “Invivogene delivery and stable transduction of nondividing cells by a lentiviral vector,”Science, 272: 263-267 (1996).
Sarkaria, Jann N. et al., “Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine,”Cancer Res., 59: 4375-4382 (1999).
Savitsky, Kinneret et al., “A single ataxia telangiectasia gene with a product similar to P1-3 kinase,”Science, 268:1749-1753 (1995).
Shiloh, Yosef,“ATM and ATR: networking cellular responses to DNA damage,”Curr. Opin. Genet. Dev., 11:71-77 (2001).
Willmore, et al., “A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia”,Blood, Jun. 15, 2004, vol. 103, No. 12, 4659-4665.
Zakian, Virginia A., “ATM-related genes: What do they tell us about functions of the human gene?”Cell, 82:685-687 (1995).
Banin, S., et al, “Enhanced phosphorylation of p53 ATM in response to DNA damage,”Science, 1998, vol. 281, pp. 1674-1677.
Bantick, J.R., et al., “Synthesis of 2-aminochromones,”J. Heterocyclic Chem., 1981, vol. 18, pp. 679-684.
Berge, et al., “Pharmaceutically acceptable salts,”J. Pharm. Sci., 1977, vol. 66, pp. 1-19.
Bettoni, et al., “Synthesis and absolute configuration of substituted morpholines,”Tetrahedron, 1980, vol. 36, pp. 409-415.
Boyd, J., et al., “The chemistry of the ‘insoluble red’ woods,”J. Chem. Soc., 1948, pp. 174-176.
Buon, C., et al., “Synthesis of 3-substituted and 2,3-disubstituted-4H-1,4- Benzoxazines,”Tetrahedron, 2000, vol. 56, pp. 605-614.
Daniel, R., et al., “A role for DNA-PK in retroviral DNA integration,”Science, 1999, vol. 284, pp. 644-647.
Datta, A., et al., “Reformatsky reaction on aroylketene S, N-acetals: a facile route to 4-amino-6-aryl-2H-pyran-2-ones,”Synthesis, 1988, vol. 3, pp. 248-250.
Di Braccio, M., et al., “1,2-fused pyrimidines VII,”Eur. J. Med., Chem., 1995, vol. 30, No. 1, pp. 27-38.
Di Braccio, M., et al., “Pyran derivatives XIX. (Dialkylamino) substituted 1-benzopyranones and naphthopyranoes with platelet antiaggregating activity,”Farmaco, 1995, vol. 50, No. 10, pp. 703-711.
Ermili, A., et al., “Chemical and pharmacological research on pyran derivatives,” Enclosed:Chemical Abstracts, 1977, vol. 87, No. 15, p. 588 (XP-002218602). 117750g.
Gell, D., et al., “Mapping of protein-protein interactions within the DNA-dependent protein kinase complex,”Nucleic Acid Res., 1999, vol. 27, No. 17, pp. 3494-3502.
Goytisolo, et al., “The absence of DNA-dependent protein kinase catalytic subunit in mice results in anaphase bridges and in increased telomeric fusions with normal telomere length and G-strand overhang,”Mol. Cell. Biol., 2001, vol. 21, No. 11, pp. 3642-3651.
Green,

Affiliated with

Also associated with

Rating

Thiopyrane-4-ones as DNA protein kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thiopyrane-4-ones as DNA protein kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiopyrane-4-ones as DNA protein kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3614560